Associate Professor Borislava Mihaylova
- Health Economics Research Centre
Borislava (Boby) Mihaylova is an Associate Professor and Senior Health Economist at the Health Economics Research Centre at the University of Oxford. Her research programme focuses on economic aspects of chronic disease (such as cardiovascular, chronic kidney disease and diabetes) and comprises studies of the impact of disease events and interventions on morbidity, mortality, health-related quality of life and healthcare costs; development of disease models to evaluate long-term effects of disease and interventions, cost-effectiveness analyses of healthcare interventions and studies of socio-economic determinants of health. She is leading the development of the economic analyses in a number of large randomised controlled trials (SHARP, THRIVE, REVEAL and ACST-2) and in the individual participant data meta-analysis of statin trials (Cholesterol Treatment Collaboration). Her work on effectiveness and cost-effectiveness of statins for cardiovascular disease prevention in the Heart Protection Study and the Cholesterol Treatment Collaboration has been influential in informing treatment recommendations for people at different vascular disease risk.
Daily life and challenges faced by households with permanent childhood developmental disability in rural Tanzania – a qualitative study
Castellani J. et al, (2021), Journal of Developmental and Physical Disabilities
Performance of the UKPDS Outcomes Model 2 in a contemporary UK type 2 diabetes trial cohort
Keng MJ. et al, (2021), Value in Health
Long-term monitoring in primary care for chronic kidney disease and chronic heart failure: a multi-method research programme
Perera R. et al, (2021), Programme Grants for Applied Research, 9, 1 - 218
Gender differences in use of invasive diagnostic procedures for acute ischaemic heart disease in Chinese adults
Levy M. et al, (2021), Heart
Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey.
Thorn JC. et al, (2021), Value Health, 24, 539 - 547